The evidence on youth gender medicine

What do the systematic reviews say about puberty blockers and cross-sex hormones for minors?

“Puberty blockers” is the common name for gonadotrophin-releasing hormone agonists, or GnRH agonists. In this context, they are prescribed to suppress the hormonal processes of puberty. “Cross-sex hormones” is a widely used but contested term; clinical documents more often use “masculinising and feminising hormones” or “gender-affirming hormones”. These include testosterone for females and oestrogen-based treatment for males, sometimes alongside medicines that suppress testosterone.

Background

“Puberty blockers” is the common name for gonadotrophin-releasing hormone agonists, or GnRH agonists. In this context, they are prescribed to suppress the hormonal processes of puberty. “Cross-sex hormones” is a widely used but contested term; clinical documents more often use “masculinising and feminising hormones” or “gender-affirming hormones”. These include testosterone for females and oestrogen-based treatment for males, sometimes alongside medicines that suppress testosterone.

The key distinction in the evidence is between a medicine doing its immediate biological job and it improving the outcomes that matter most to a young person over time. The reviews consistently find that blockers suppress sex hormones and that masculinising or feminising hormones induce some expected bodily changes. The more difficult questions are whether these interventions reduce gender-related distress, improve mental health or quality of life, and what their effects are on bone density, fertility, sexual development, cognition and later adult wellbeing.

Systematic reviews do not simply count favourable studies. They ask whether studies have suitable comparison groups, enough participants, adequate follow-up and methods capable of separating treatment effects from normal development, regression to the mean, concurrent therapy, family support, changing circumstances and selection bias. This matters especially where almost all participants expect treatment to help and where untreated comparison groups are scarce.

What the documents say

Puberty blockers

NICE’s evidence review, prepared in October 2020 for NHS England, included nine observational studies: five retrospective studies, three prospective longitudinal studies and one cross-sectional study. Seven used before-and-after comparisons within the treated group. NICE rated evidence on gender dysphoria, mental health, body image and psychosocial functioning as very low certainty. It also found no cost-effectiveness evidence. The review did not conclude that blockers have no benefit; rather, it found that the available evidence could not establish a reliable estimate of benefit or harm (NICE, 2020).

The later University of York systematic review, led by Jo Taylor and published in Archives of Disease in Childhood in April 2024, included 50 studies: 11 cohort studies, eight cross-sectional studies and 31 pre-post studies. Its conclusion was direct: no high-quality studies using an appropriate design to assess puberty-suppression outcomes were identified. The authors found that GnRH agonists reliably suppress gonadotrophins and sex steroids, but concluded that evidence about gender dysphoria, mental health, psychosocial outcomes and cognitive development was insufficient to draw firm conclusions. They also reported concern about bone mineral density during treatment and uncertainty about longer-term outcomes (Taylor et al., 2024).

The Cass Review, led by paediatrician Dr Hilary Cass and published on 10 April 2024, drew on the York reviews, NICE work and other evidence. It stated that the rationale for early puberty suppression remained unclear, that evidence of effects on distress and mental or psychosocial health was weak, and that bone density was compromised during suppression. It recommended that puberty blockers for this group should be available only within a research protocol.

Masculinising and feminising hormones

The companion York review assessed 53 studies of masculinising and feminising hormone treatment in adolescents. It included 12 cohort studies, nine cross-sectional studies and 32 pre-post studies. One cohort study was judged high quality, 33 studies moderate quality and 19 low quality. Most studies included adolescents who had also received puberty suppression, making it difficult to isolate the effect of hormones alone (Taylor et al., 2024).

The review found moderate-quality evidence, largely from short pre-post studies, suggesting that psychological health may improve during hormone treatment. But it found limited or inconsistent evidence on gender dysphoria, body satisfaction, psychosocial health, cognitive outcomes and fertility. It could draw no conclusions on several longer-term physical outcomes, including growth, bone health and cardiometabolic health. The authors’ bottom line was not that all benefits are absent; it was that high-quality, long-term research is lacking and that robust studies remain necessary.

This is an important correction to two common slogans. “There is no evidence” is too absolute, because there are studies and some report improvements. “The evidence proves treatment is safe and effective” is also too strong, because the systematic reviews repeatedly find that the evidence is low certainty, short term, confounded or unable to answer central questions.

The positions

The gender-affirming position holds that carefully assessed young people can benefit from puberty blockers or hormones, particularly where unwanted pubertal development causes severe distress. The World Professional Association for Transgender Health’s Standards of Care, version 8, published in 2022, supports individualised assessment and access to indicated treatment. In its May 2024 response to Cass, WPATH and USPATH argued that their recommendations rested on a broader body of systematic reviews and clinical consensus. They also argued that withholding treatment may worsen distress and that randomised controlled trials may be ethically difficult in this field (WPATH and USPATH, 2024).

Critics of the Cass approach argue that observational evidence is normal in paediatric medicine, that randomised trials may be impractical or unethical, and that evidence reviews must account for the harm of withholding desired treatment. They further argue that the focus on study-design limitations can underweight patient-reported benefit and clinical experience.

The more cautious position, adopted by Cass, NHS England and the UK Commission on Human Medicines, is that ordinary clinical uncertainty is not enough to justify routine medical intervention in minors where effects may shape development and where long-term outcomes remain unclear. NHS England ended routine commissioning of puberty blockers for under-18s on 12 March 2024. The Commission on Human Medicines subsequently advised that the existing prescribing environment presented an unacceptable safety risk, supporting an indefinite UK restriction on new private prescribing for this indication.

Interpretation

Beyond Gender’s reading is that the systematic reviews do not provide a sound evidential basis for presenting puberty blockers as a proven, low-risk “pause button”, nor cross-sex hormones for minors as an established treatment with known long-term benefit-to-harm balance. That is an interpretation of the evidence reviews, not a claim that every individual who receives these interventions is harmed or that no young person reports benefit.

The most significant finding is methodological, rather than ideological: studies have generally been too weak to answer the questions that matter. A treatment pathway can be biologically effective at suppressing puberty or inducing secondary sex characteristics while still lacking reliable evidence that it improves a minor’s overall long-term wellbeing. In a population with substantial developmental change, co-occurring mental-health needs and varied pathways into gender distress, this distinction should be central to informed consent.

The evidence also challenges the language of certainty. “Reversible” accurately describes the resumption of endogenous puberty after stopping GnRH agonists in a narrow pharmacological sense. It does not by itself answer whether bone accrual, psychosexual development, fertility-related outcomes or the consequences of moving from blockers to hormones are fully reversible. The reviews identify these as unresolved areas, not settled science.

Open questions

Better research must compare clearly defined care pathways, including comprehensive psychosocial support, watchful waiting where appropriate, puberty suppression and hormones. It should follow participants into adulthood, report outcomes separately for females and males, distinguish those who receive blockers before hormones from those who do not, and measure physical as well as psychological outcomes.

Research also needs to address fertility, bone density and fracture risk, sexual function and development, cognition, cardiovascular and metabolic outcomes, treatment discontinuation, regret and detransition. It should investigate which young people, if any, have a favourable benefit-to-harm balance, rather than assuming that a highly heterogeneous group can be treated as clinically uniform.

Finally, policy should not leave distressed young people without care. The evidence gap is not an argument for neglect. It is an argument for thorough assessment, support for families, treatment of co-occurring anxiety, depression, trauma or neurodevelopmental needs, and research capable of giving future patients and clinicians answers stronger than hope, fear or assertion.

On the timeline

Episodes on this idea

Rethinking Youth Gender Medicine with Dr Louise Irvine

The Doctors Transitioned My Son at 13 - Here’s What Happened Next...